Uroplasty, Inc. Is Being Investigated on Behalf of Shareholders

Robbins LLP is investigating whether officers and directors of Uroplasty, Inc. (NASDAQCM: UPI) breached their fiduciary duties to shareholders. Uroplasty, a medical device company, develops, manufactures, and markets products for the treatment of voiding dysfunctions.

Robbins Investigates Uroplasty's Potential Improper Public Statements Regarding Internal Controls

Robbins investigation concerns whether certain of Uroplasty's officers and directors failed to implement adequate internal financial controls. On June 14, 2013, the company announced a delay in the filing of its annual report on Form 10-K for the year ended March 31, 2013, following the completion of a review of its internal control over financial reporting. Specifically, the company announced that it had recently discovered problems with internal controls related to expense reimbursement for its employees and that upon conducting a review of the issues, Uroplasty found additional problems related to the recognition of orders and payment of sales commissions at the end of its fiscal quarters. Further, the company announced that it placed its Chief Financial Officer, Mahedi Jiwani, on administrative leave pending a complete investigation of the company's internal controls.

On this news, shares of Uroplasty dropped $0.26, or 10.5%, to close at $2.22 on June 14, 2013, and have continued to decline an additional 14%, closing at $2.02 on July 1, 2013.

Robbins LLP highlights that Uroplasty shareholders have the option to pursue a shareholder derivative action through which shareholders aim to hold insider wrongdoers accountable for their actions, prevent future misconduct, and bring long-term value back to the company.

Uroplasty shareholders who would like more information about their rights and potential remedies can complete the form below and we will contact you directly. You can also contact attorney Darnell R. Donahue at (800) 350-6003.